XML 31 R21.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Balance Sheet Components (Tables)
3 Months Ended
Mar. 31, 2024
Balance Sheet Related Disclosures [Abstract]  
Schedule of Prepaid Expenses and Other Current Assets

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following:

 

 

 

March 31,

 

 

December 31,

 

 

 

2024

 

 

2023

 

 

 

(in thousands)

 

Prepaid research and development costs ($9.4 million and $6.3
    million from related party in 2024 and 2023, respectively)

 

$

14,603

 

 

$

19,085

 

Prepaid other

 

 

4,561

 

 

 

4,273

 

Other receivables

 

 

906

 

 

 

939

 

Total prepaid expenses and other current assets

 

$

20,070

 

 

$

24,297

 

 

Schedule of Accrued Liabilities

Accrued Liabilities

Accrued liabilities consisted of the following:

 

 

 

March 31,

 

 

December 31,

 

 

 

2024

 

 

2023

 

 

 

(in thousands)

 

Compensation and benefits

 

$

4,660

 

 

$

10,011

 

Accrued research and development services ($6.3 million and $3.1 
     million due to related party in 2024 and 2023, respectively)

 

 

7,442

 

 

 

5,004

 

Professional services

 

 

926

 

 

 

787

 

Accrued clinical trial and preclinical costs

 

 

5,923

 

 

 

4,705

 

Other

 

 

542

 

 

 

750

 

Total accrued liabilities

 

$

19,493

 

 

$

21,257